menu
    • menu
    [{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ABI-011","moa":"Angiogenesis (AGG)","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Hematology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Hematology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"OncoMed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Demcizumab","moa":"Delta-like protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"OncoMed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Demcizumab","moa":"Delta-like protein 4","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"OncoMed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"Dihydrofolate reductase | Thymidylate synthase | GAR transformylase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"EPZ-5676","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin Vaccine","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"CC-90001","moa":"JNK kinase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"CC-90001","moa":"JNK kinase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celularity","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Cenplacel-L","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CC-292","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"CC-292","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMS-986393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celularity","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Placenta Derived Cell PDA001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celularity","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Placenta Derived Cell PDA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"UMC Utrecht","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ UMC Utrecht","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ UMC Utrecht"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Paul Richardson, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Paul Richardson, MD","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Paul Richardson, MD"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Thomas Kipps","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Thomas Kipps","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Thomas Kipps"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Jun Zhang","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Jun Zhang","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Jun Zhang"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"David Rizzieri","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ David Rizzieri","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ David Rizzieri"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Steven P. Treon, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Steven P. Treon, MD, PhD","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Steven P. Treon, MD, PhD"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Ajai Chari","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Ajai Chari","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Ajai Chari"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Michaela Liedtke","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amrubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Michaela Liedtke","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Michaela Liedtke"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sherif S. Farag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Sherif S. Farag","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Sherif S. Farag"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Weiyun Ai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Weiyun Ai","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Weiyun Ai"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Priyanka Sharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Priyanka Sharma","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Priyanka Sharma"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Professor Mikkel \u00d8stergaard","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Professor Mikkel \u00d8stergaard","highestDevelopmentStatusID":"11","companyTruncated":"Celgene Corporation \/ Professor Mikkel \u00d8stergaard"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Julian M. Mackay-Wiggan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Julian M. Mackay-Wiggan","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Julian M. Mackay-Wiggan"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Jean-Luc Van Laethem","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Jean-Luc Van Laethem","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Jean-Luc Van Laethem"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Muhammad Furqan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Muhammad Furqan","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Muhammad Furqan"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Al B. Benson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Al B. Benson","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Al B. Benson"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"John Mascarenhas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ John Mascarenhas","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ John Mascarenhas"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Carlos Graux","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Lymphocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celgene Corporation \/ Carlos Graux","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Carlos Graux"}]

    Find Clinical Drug Pipeline Developments & Deals by Celgene Corporation

    Menu

    Celgene Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986393

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With R...

                            Details : BMS-986393 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : BMS-986393

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed o...

                            Details : Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Follicular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2024

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozanimod

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bristol Myers Releases Data Reinforcing Zeposia's Efficacy in MS

                            Details : Zeposia (ozanimod) is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. It is indicated for relapsing forms of multiple sclerosis.

                            Product Name : Zeposia

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : Ozanimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enasidenib,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML

                            Details : Idhifa (enasidenib) is an isocitrate dehydrogenase-2 inhibitor, which is being evaluated in combination with venetoclax for the treatment of IDH2 gene mutated acute myeloid leukemia.

                            Product Name : Idhifa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : Enasidenib,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CC-97540

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap...

                            Details : CC-97540 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 23, 2024

                            Lead Product(s) : CC-97540

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisocabtagene Maraleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adu...

                            Details : Breyanzi (Lisocabtagene Maraleucel) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.

                            Product Name : Breyanzi

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Lisocabtagene Maraleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Juno Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Leipzig

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Tra...

                            Details : Luspatercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Leipzig

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enasidenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

                            Details : Enasidenib mesylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 16, 2022

                            Lead Product(s) : Enasidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sun Pharma Settles generic Revlimid Patent Litigation in US

                            Details : Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime...

                            Product Name : Revlimid

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Celgene Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fedratinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of...

                            Details : Fedratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : Fedratinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth